LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the first patient implant in a U.S. Food ...
Disc Medicine Inc. CEO John Quisel said that top-line phase II findings from the study called Aurora with bitopertin in erythropoietic protoporphyria are “hard for us to interpret. This package of ...
Disc Medicine announced it received a Commissioner's National Priority Voucher from the US FDA for bitopertin in erythropoietic protoporphyria and submitted a New Drug Application seeking accelerated ...
Disc Medicine, Inc. announced its plans for 2025, highlighting key developments in its clinical programs focused on hematologic diseases. The company will discuss plans for NDA submission of ...
The U.S. FDA named the first nine recipients of the recently unveiled commissioner’s national priority voucher (CNPV) program ...
WAYLAND, Mass. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX) (“Gemini”) and Disc Medicine, Inc. (“Disc”), a privately-held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback